Suppr超能文献

阻止慢性肾病进展:时机即将到来。

Stop chronic kidney disease progression: Time is approaching.

作者信息

Sharaf El Din Usama Abdel Azim, Salem Mona Mansour, Abdulazim Dina Ossama

机构信息

Usama Abdel Azim Sharaf El Din, Departments of Nephrology, School of Medicine, Cairo University, Manial, Cairo 11759, Egypt.

出版信息

World J Nephrol. 2016 May 6;5(3):258-73. doi: 10.5527/wjn.v5.i3.258.

Abstract

Progression of chronic kidney disease (CKD) is inevitable. However, the last decade has witnessed tremendous achievements in this field. Today we are optimistic; the dream of withholding this progression is about to be realistic. The recent discoveries in the field of CKD management involved most of the individual diseases leading the patients to end-stage renal disease. Most of these advances involved patients suffering diabetic kidney disease, chronic glomerulonephritis, polycystic kidney disease, renal amyloidosis and chronic tubulointerstitial disease. The chronic systemic inflammatory status and increased oxidative stress were also investigated. This inflammatory status influences the anti-senescence Klotho gene expression. The role of Klotho in CKD progression together with its therapeutic value are explored. The role of gut as a major source of inflammation, the pathogenesis of intestinal mucosal barrier damage, the role of intestinal alkaline phosphatase and the dietary and therapeutic implications add a novel therapeutic tool to delay CKD progression.

摘要

慢性肾脏病(CKD)的进展是不可避免的。然而,过去十年在该领域取得了巨大成就。如今我们满怀希望;阻止这种进展的梦想即将成为现实。CKD管理领域的最新发现涉及导致患者发展至终末期肾病的大多数个体疾病。这些进展大多涉及患有糖尿病肾病、慢性肾小球肾炎、多囊肾病、肾淀粉样变性和慢性肾小管间质性疾病的患者。慢性全身性炎症状态和氧化应激增加也得到了研究。这种炎症状态会影响抗衰老的Klotho基因表达。探讨了Klotho在CKD进展中的作用及其治疗价值。肠道作为炎症的主要来源的作用、肠黏膜屏障损伤的发病机制、肠碱性磷酸酶的作用以及饮食和治疗意义为延缓CKD进展增添了一种新的治疗手段。

相似文献

1
Stop chronic kidney disease progression: Time is approaching.
World J Nephrol. 2016 May 6;5(3):258-73. doi: 10.5527/wjn.v5.i3.258.
3
The role of klotho in chronic kidney disease.
BMC Nephrol. 2018 Oct 22;19(1):285. doi: 10.1186/s12882-018-1094-z.
5
Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy.
Kidney Int. 2017 May;91(5):1104-1114. doi: 10.1016/j.kint.2016.10.034. Epub 2017 Jan 25.
8
FGF23 and Klotho in chronic kidney disease.
Curr Opin Nephrol Hypertens. 2013 Jul;22(4):397-404. doi: 10.1097/MNH.0b013e32836213ee.
9
Downregulation of kidney protective factors by inflammation: role of transcription factors and epigenetic mechanisms.
Am J Physiol Renal Physiol. 2016 Dec 1;311(6):F1329-F1340. doi: 10.1152/ajprenal.00487.2016. Epub 2016 Oct 19.
10
[Risk factors for anemia in the early stages of chronic kidney disease].
Ter Arkh. 2017;89(6):41-47. doi: 10.17116/terarkh201789641-47.

引用本文的文献

3
A novel fusion protein consisting of anti-ANGPTL3 antibody and interleukin-22 ameliorates diabetic nephropathy in mice.
Front Immunol. 2022 Dec 5;13:1011442. doi: 10.3389/fimmu.2022.1011442. eCollection 2022.
5
Effect of Age and Acute-Moderate Intensity Exercise on Biomarkers of Renal Health and Filtration.
Biology (Basel). 2022 Mar 30;11(4):527. doi: 10.3390/biology11040527.
7
Hepatic Steatosis Index and Chronic Kidney Disease among Middle-Aged Individuals: A Large-Scale Study in Japan.
Dis Markers. 2021 Jun 9;2021:9941834. doi: 10.1155/2021/9941834. eCollection 2021.
8
Klotho alleviates indoxyl sulfate-induced heart failure and kidney damage by promoting M2 macrophage polarization.
Aging (Albany NY). 2020 May 28;12(10):9139-9150. doi: 10.18632/aging.103183.

本文引用的文献

1
The Isolation and Quantitation of Fetuin-A-Containing Calciprotein Particles from Biological Fluids.
Methods Mol Biol. 2016;1397:221-240. doi: 10.1007/978-1-4939-3353-2_15.
2
Klotho Ameliorates Kidney Injury and Fibrosis and Normalizes Blood Pressure by Targeting the Renin-Angiotensin System.
Am J Pathol. 2015 Dec;185(12):3211-23. doi: 10.1016/j.ajpath.2015.08.004. Epub 2015 Oct 24.
3
Probiotics and chronic kidney disease.
Kidney Int. 2015 Nov;88(5):958-66. doi: 10.1038/ki.2015.255. Epub 2015 Sep 16.
4
Gut microbiome in chronic kidney disease.
Exp Physiol. 2016 Apr;101(4):471-7. doi: 10.1113/EP085283. Epub 2015 Oct 2.
5
Low-Dose IL-17 Therapy Prevents and Reverses Diabetic Nephropathy, Metabolic Syndrome, and Associated Organ Fibrosis.
J Am Soc Nephrol. 2016 Mar;27(3):745-65. doi: 10.1681/ASN.2014111136. Epub 2015 Sep 2.
7
Tempol, a Superoxide Dismutase-Mimetic Drug, Ameliorates Progression of Renal Disease in CKD Mice.
Cell Physiol Biochem. 2015;36(6):2170-82. doi: 10.1159/000430183. Epub 2015 Jul 21.
8
The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.
Lancet Diabetes Endocrinol. 2015 Sep;3(9):687-96. doi: 10.1016/S2213-8587(15)00261-2. Epub 2015 Aug 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验